



Association between length of stay and postoperative survival in patients with lung cancer: a propensity score matching analysis based on National Cancer Database

Weicheng Kong^{1#}, Haoran Wang^{2,3#}, Yanyan Chen^{4,5}, Juntao Xie⁶, Binhao Huang^{5,7}, Liang Fang⁸, Wenjuan Chen⁹, Wei Shao¹⁰, Jie Zhang^{3,5}

¹Department of Thoracic Surgery, Putuo District People's Hospital, Zhoushan, China; ²Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China; ³Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China; ⁴Division of Pulmonary, SinoUnited Health, Shanghai, China; ⁵Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; ⁶Department of Surgery, Shanghai Putuo District People's Hospital, Shanghai, China; ⁷Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; ⁸Department of General Medicine, Xinzhou District Second People's Hospital, Shangrao, China; ⁹Department of Intensive Care Unit, Putuo District People's Hospital, Zhoushan, China; ¹⁰Department of Interventional Therapy, Putuo District People's Hospital, Zhoushan, China

Contributions: (I) Conception and design: W Kong, H Wang, J Zhang; (II) Administrative support: J Zhang; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Wei Shao, MD. Department of Interventional Therapy, Putuo District People's Hospital, 19 Wenkang Road, Zhoushan 316100, China. Email: shao9787@163.com; Jie Zhang, MD. Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 Huaihai Road West, Shanghai 200030, China; Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Email: zhangjie2289@hotmail.com.

Background: Postoperative complications tend to result in prolonged hospitalization. The aim of this study was to investigate whether prolonged postoperative length of stay (LOS) can predict patient survival, particularly long-term survival.

Methods: All patients undergoing lung cancer surgery between 2004 and 2015 were identified in the National Cancer Database (NCDB). The highest quintile of LOS (more than 8 days) was defined as prolonged length of stay (PLOS). We performed 1:1 propensity score matching (PSM) between the groups with and without PLOS (Non-PLOS). Excluding confounding factors, postoperative LOS was used as a surrogate for postoperative complications. Kaplan-Meier and Cox proportional hazards survival analyses were performed to analyze survival.

Results: A total of 88,007 patients were identified. After matching, 18,585 patients were enrolled in the PLOS and Non-PLOS groups, respectively. Before and after matching, 30-day rehospitalization rate and 90-day mortality in the PLOS group were significantly higher than they were in the Non-PLOS group ($P < 0.001$), indicating a potential worse short-term postoperative survival. After matching, the median survival of the PLOS group was significantly lower than that of the Non-PLOS group (53.2 vs. 63.5 months, $P < 0.0001$). Multivariable analysis revealed that PLOS is independent negative predictor of overall survival [OS; hazard ratio (HR) = 1.263, 95% confidence interval (CI): 1.227 to 1.301, $P < 0.001$]. In addition, age (< 70 or ≥ 70), gender, race, income, year of diagnosis, surgery type, pathological stage, and neoadjuvant therapy also were independent prognostic factors of postoperative survival for patients with lung cancer (all $P < 0.001$).

Conclusions: Postoperative LOS could be taken as the quantitative indicator of postoperative complications of lung cancer in NCDB. In this study, PLOS predicted worse short-term and long-term survival independent of other factors. Avoiding PLOS could be considered to benefit patient survival after lung cancer surgery.

Keywords: Lung cancer; prolonged length of stay (PLOS); postoperative survival; postoperative complications

Submitted Dec 06, 2022. Accepted for publication Apr 21, 2023. Published online Apr 26, 2023.

doi: 10.21037/jtd-23-407

View this article at: <https://dx.doi.org/10.21037/jtd-23-407>

Introduction

Presently, lung cancer remains the leading cause of cancer-related death worldwide (1). Surgical treatment is currently recommended as the preferred therapeutic approach for resectable lung cancer (2). In recent years, the concept of enhanced recovery after surgery (ERAS) was proposed in surgical management of lung cancer, namely, to optimize perioperative treatment, reduce perioperative stress response and postoperative complications, shorten hospitalization time, and promote recovery (3,4). In the past few years, the length of stay (LOS) following thoracic surgery has been used as a quality metric for assessing the efficiency of a healthcare unit (5). However, there are few studies on the effect of postoperative LOS on survival of patients with lung cancer.

The National Cancer Database (NCDB) is a clinical oncology database co-sponsored by American College of Surgeons Commission on Cancer and the American Cancer Society, which is originated from the hospital registration data collected in more than 1,500 institutions recognized by the Cancer Committee, which can be applied to analyze and track patients with malignant tumors, as well as their treatments and outcomes (6). However, there is no records about complications in NCDB, therefore here we aimed to determine whether prolonged length of stay (PLOS) can

serve as an independent prognostic factor for postoperative survival of patients with lung cancer. In the present study, LOS was first proposed as an alternative quantitative indicator of postoperative complications in NCDB lung cancer patients. We present the following article in accordance with the STROBE reporting checklist (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-407/rc>).

Methods

Patient enrollment

Patients with lung cancer who underwent surgical treatment in the NCDB database from 2004 to 2015 were enrolled in this study, and their clinical data were retrospectively analyzed. The inclusion criteria included a history of surgery, and lung cancer in clinical stage I–III (6th and 7th editions). The exclusion criteria were as follows: absence of information regarding LOS, follow-up, and other clinical data; death within 30 days after surgery; follow-up period less than 3 months (*Figure 1*). After screening, the target population for our subsequent analysis was finally obtained. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Study design

In this study, the LOS range of the included cases was 1–167 days. According to the quartile method, patients was divided into quartiles. Patients in the highest quartile were listed as the PLOS group, and the value was calculated to be more than 8 days. The remaining patients were classified as the Non-PLOS group. Deviation between the PLOS group and the Non-PLOS group was controlled by 1:1 propensity score matching (PSM) based on age, gender, race, facility type, income, insurance, Charlson/Deyo Score, year of diagnosis, laterality, clinical stage, histology type, tumor grade, surgery type, surgical margins, pathological stage, neoadjuvant therapy, and adjuvant therapy. Standardized mean difference (SMD) was calculated to

Highlight box

Key findings

- Patients with PLOS exhibited worse short-term and long-term survival.

What is known and what is new?

- In the past few years, LOS following thoracic surgery has been used as a quality metric for assessing the efficiency of a healthcare unit.
- LOS was first proposed as an alternative quantitative indicator of postoperative complications in NCDB lung cancer patients.

What is the implication, and what should change now?

- Avoiding PLOS could be considered to benefit patient survival after lung cancer surgery.




Figure 1 Patient selection flowchart. Included patients were screened sequentially following the exclusion criteria.

evaluate the balance of baseline data between the 2 groups before and after PSM. A SMD <0.1 was considered the balanced distribution of baseline data. We selected 30-day rehospitalization rate and 90-day mortality in the PLOS group as the short-term survival indicators. The overall survival (OS) was considered the long-term survival index.

Statistical analysis

The software SPSS 25.0 (IBM Corp., Armonk, NY, USA) was used for all data analysis. Chi-square test and multivariable logistic regression analysis were used to evaluate the long-term and short-term prognostic survival before and after PSM. Kaplan-Meier analysis was used to calculate the survival rate and draw the survival curve. Log-rank test was used to compare the survival curve. Cox proportional-hazards model was used for multivariable analysis to adjust the long-term survival prognosis of patients. All statistical tests were 2-sided, and $P < 0.05$ was considered statistically significant.

Results

Clinical characteristics

After screening, a total of 88,007 patients were enrolled in the study (Figure 1). According to the quartile of the LOS, patients hospitalized for more than 8 days were defined as the PLOS group ($n=18,611$, 21.1%), and the remaining

patients as the Non-PLOS group ($n=69,396$, 78.9%). We compared the clinical characteristics between the PLOS and Non-PLOS groups (Table 1). Before PSM, there was an imbalance in baseline distribution between the PLOS group and the Non-PLOS group (SMD ≥ 0.1). After PSM, there were 18,585 cases in each of the PLOS group and Non-PLOS groups, with balanced variables (SMD <0.1).

The effect of the PLOS on the short-term survival

Focusing on the short-term survival, we found that 30-day re-hospitalization rate and 90-day mortality in the PLOS group were significantly higher than those in the Non-PLOS group before and after PSM ($P < 0.001$), indicating a less favorable short-term prognosis in the PLOS group (Table 2). Further, multivariable logistic regression analysis also revealed that PLOS was an independent negative predictor of short-term postoperative survival of lung cancer patients ($P < 0.001$).

The effect of PLOS on the long-term survival

For further study, we compared the Kaplan-Meier OS curve in the PLOS group and the Non-PLOS group before and after PSM (Figure 2). Before PSM, the median survival of the PLOS group and the Non-PLOS group was 82.1 months [95% confidence interval (CI): 80.9 to 83.3 months] and 53.2 months (95% CI: 51.6 to 54.3 months), respectively ($P < 0.0001$). After PSM, the

Table 1 Baseline patient clinical characteristics before and after PSM

Clinical characteristics	Before matching			After matching		
	Non-PLOS	PLOS	SMD	Non-PLOS	PLOS	SMD
N	69,396	18,611		18,585	18,585	
Age, years, mean $\pm$ SD	66.52 $\pm$ 9.82	67.76 $\pm$ 9.43	0.128	67.66 $\pm$ 9.61	67.75 $\pm$ 9.43	0.009
Gender, n (%)			0.167			0.013
Male	31,797 (45.8)	10,075 (54.1)		9,928 (53.4)	10,051 (54.1)	
Female	37,599 (54.2)	8,536 (45.9)		8,657 (46.6)	8,534 (45.9)	
Race, n (%)			0.051			0.019
White	61,123 (88.1)	16,542 (88.9)		16,548 (89.0)	16,517 (88.9)	
Black	5,907 (8.5)	1,595 (8.6)		1,521 (8.2)	1,594 (8.6)	
Other	2,366 (3.4)	474 (2.5)		516 (2.8)	474 (2.6)	
Income, n (%)			0.134			0.015
<\$48,000	28,644 (41.3)	8,923 (47.9)		8,763 (47.2)	8,898 (47.9)	
$\geq$ \$48,000	40,752 (58.7)	9,688 (52.1)		9,822 (52.8)	9,687 (52.1)	
Insurance, n (%)			0.012			0.001
No insured	1,396 (2.0)	406 (2.2)		406 (2.2)	406 (2.2)	
Insured	68,000 (98.0)	18,205 (97.8)		18,179 (97.8)	18,179 (97.8)	
Urban/rural location, n (%)			0.033			0.001
Metro/urban counties	67,881 (97.8)	18,109 (97.3)		18,081 (97.3)	18,085 (97.3)	
Rural counties	1,515 (2.2)	502 (2.7)		504 (2.7)	500 (2.7)	
Facility type, n (%)			0.142			0.009
Non-academic	42,317 (61.0)	12,607 (67.7)		12,660 (68.1)	12,582 (67.7)	
Academic	27,079 (39.0)	6,004 (32.3)		5,925 (31.9)	6,003 (32.3)	
Charlson Comorbidity Index score, n (%)			0.217			0.055
0	35,202 (50.7)	7,508 (40.3)		7,913 (42.6)	7,508 (40.4)	
1	24,744 (35.7)	7,661 (41.2)		7,167 (38.6)	7,656 (41.2)	
$\geq$ 2	9,450 (13.6)	3,442 (18.5)		3,505 (18.9)	3,421 (18.4)	
Year of diagnosis, n (%)			0.150			0.076
2004–2009	21,759 (31.4)	7,161 (38.5)		7,828 (42.1)	7,139 (38.4)	
2010–2015	47,637 (68.6)	11,450 (61.5)		10,757 (57.9)	11,446 (61.6)	
Laterality			0.063			
Right	40,272 (58.0)	11,379 (61.1)		11,285 (60.7)	11,360 (61.1)	0.008
Left	29,124 (42.0)	7,232 (38.9)		7,300 (39.3)	7,225 (38.9)	
Clinical stage			0.070			0.049
I	51,124 (73.7)	13,157 (70.7)		13,241 (71.2)	13,147 (70.7)	
II	10,860 (15.6)	3,353 (18.0)		3,053 (16.4)	3,344 (18.0)	
III	7,412 (10.7)	2,101 (11.3)		2,291 (12.3)	2,094 (11.3)	

Table 1 (continued)

Table 1 (continued)

Clinical characteristics	Before matching			After matching		
	Non-PLOS	PLOS	SMD	Non-PLOS	PLOS	SMD
Histology type, n (%)			0.202			0.091
Adenocarcinoma	41,110 (59.2)	9,355 (50.3)		9,690 (52.1)	9,350 (50.3)	
Squamous cell carcinoma	18,601 (26.8)	6,653 (35.7)		5,909 (31.8)	6,642 (35.7)	
Other	9,685 (14.0)	2,603 (14.0)		2,986 (16.1)	2,593 (14.0)	
Grade, n (%)			0.180			0.055
Well differentiated	11,803 (17.0)	2,075 (11.1)		2,278 (12.3)	2,075 (11.2)	
Moderately differentiated	31,252 (45.0)	8,434 (45.3)		8,009 (43.1)	8,431 (45.4)	
Poorly differentiated	25,156 (36.2)	7,705 (41.4)		7,831 (42.1)	7,687 (41.4)	
Undifferentiated	1,185 (1.7)	397 (2.1)		467 (2.5)	392 (2.1)	
Surgery type, n (%)			0.034			0.036
Sublobe/lobectomy	65,913 (95.0)	17,803 (95.7)		17,636 (94.9)	17,777 (95.7)	
Pneumonectomy	3,483 (5.0)	808 (4.3)		949 (5.1)	808 (4.3)	
Surgical margin, n (%)			0.058			0.008
No residual tumor	66,014 (95.1)	17,457 (93.8)		17,402 (93.6)	17,437 (93.8)	
Residual tumor present	3,382 (4.9)	1,154 (6.2)		1,183 (6.4)	1,148 (6.2)	
Pathological stage, n (%)			0.076			0.066
I	45,407 (65.4)	11,550 (62.1)		11,977 (64.4)	11,542 (62.1)	
II	14,187 (20.4)	4,346 (23.4)		3,838 (20.7)	4,332 (23.3)	
III	9,334 (13.5)	2,586 (13.9)		2,615 (14.1)	2,582 (13.9)	
IV	468 (0.7)	129 (0.7)		155 (0.8)	129 (0.7)	
Neoadjuvant therapy, n (%)			0.009			0.016
No	66,546 (95.9)	17,812 (95.7)		17,727 (95.4)	17,787 (95.7)	
Yes	2,850 (4.1)	799 (4.3)		858 (4.6)	798 (4.3)	
Adjuvant therapy, n (%)			0.079			0.025
No	52,142 (75.1)	14,605 (78.5)		14,390 (77.4)	14,579 (78.4)	
Yes	17,254 (24.9)	4,006 (21.5)		4,195 (22.6)	4,006 (21.6)	

PSM, propensity score matching; PLOS, prolonged length of stay; SMD, standardized mean difference, values <0.1 indicates acceptable balance; SD, standard deviation.

median survival of the PLOS group and the Non-PLOS group was 63.5 months (95% CI: 62.0 to 65.0 months) and 53.2 months (95% CI: 51.8 to 54.5 months), respectively ($P<0.0001$). Both results indicated a less favorable long-term prognosis in the PLOS group compared with the Non-PLOS group. Multivariable Cox regression analysis (Table 3) revealed that PLOS was an independent negative

predictor for long-term survival of patients with lung cancer [hazard ratio (HR) =1.263, 95% CI: 1.227 to 1.301, $P<0.001$]. In addition, age (<70/≥70 years), gender, race, income, year of diagnosis, surgery type, pathological stage, and neoadjuvant therapy also were independent prognostic factors of postoperative survival for patients with lung cancer ($P<0.001$, respectively).

Discussion

The current study mainly focused on the prognosis of lung cancer and its clinicopathological features including tumor size, lymph node metastasis, and distant metastasis,

Table 2 Characteristics and multivariate analysis of short-term outcomes

Variates	Unplanned readmission within 30 days	90-day mortality
Before matching, n (%)		
Non-PLOS	2,703 (3.9)	492 (0.7)
PLOS	1,147 (6.2)	544 (2.9)
P value	<0.001	<0.001
After matching, n (%)		
Non-PLOS	781 (4.2)	195 (1.0)
PLOS	1,147 (6.2)	541 (2.9)
P value	<0.001	<0.001
Multivariate (LOS): Non-PLOS vs. PLOS		
Adjusted OR	1.365	2.087
95% CI	1.247–1.495	1.799–2.421
P value	<0.001	<0.001

PLOS, prolonged length of stay; LOS, length of stay; OR, odds ratio; CI, confidence interval.

as well as patient's self-factors, such as nutritional status, autoimmune status, and psychological status (7-10). Based on the NCDB database, PSM was performed according to age, gender, race, facility type, income, insurance, Charlson Comorbidity Index score, year of diagnosis, laterality, clinical stage, histology type, tumor grade, surgery type, surgical margins, pathological stage, neoadjuvant therapy, and adjuvant therapy in this study. After PSM, the distribution of variables in PLOS group and Non-PLOS group showed a balance (SMD <0.1).

PLOS can be attributed to various factors. A large cohort study of non-cardiothoracic surgery showed that age and anesthesia duration were risk factors for prolonged postoperative hospital stay in patients undergoing thoracoscopic single lobectomy (11). In a retrospective study of 729 TV-assisted or robot-assisted thoracoscopic lobe or segment resection for lung cancer, single segment resection, two lobes or combined lobe and segment resection, and right lobectomy were independent risk factors for postoperative pulmonary complications and were associated with increased postoperative hospitalization and total hospital cost (12). In addition, prior preoperative patient medical history may also affect the length of hospital stay, which is expressed with Charlson Comorbidity Index score in the NCDB database. Here we considered above all factors which may affect length of stay during PSM. After excluding the above factors, PLOS tends to be caused by




Figure 2 Kaplan-Meier analysis for patients before and after matching. Survival curves were compared between PLOS and Non-PLOS groups. Dashed lines indicate median survival. PSM, propensity score matching; PLOS, prolonged length of stay.

Table 3 Multivariate analysis for long-term survival

Covariates	Overall survival		
	Adjusted HR	95% CI	P value
Length of stay			<0.001
Non-PLOS vs. PLOS	1.263	1.227–1.301	
Age			<0.001
<70 vs. ≥70 years	1.486	1.442–1.532	
Sex			<0.001
Male vs. female	0.782	0.759–0.806	
Race			<0.001
White	–	–	
Black	0.948	0.897–1.002	
Other	0.719	0.650–0.796	
Income			<0.001
<\$48,000 vs. ≥\$48,000	0.920	0.893–0.948	
Urban/rural location			0.055
Urban vs. rural	1.089	0.998–1.189	
Year of diagnosis			<0.001
2004–2009 vs. 2010–2015	0.685	0.664–0.706	
Laterality			0.681
Right vs. left	1.006	0.977–1.037	
Surgery type			<0.001
Sub/lobectomy vs. pneumonectomy	1.241	1.166–1.320	
Pathological stage			<0.001
I	–	–	
II	1.707	1.642–1.774	
III	2.411	2.306–2.519	
IV	2.998	2.620–3.343	
Neoadjuvant therapy			<0.001
Yes vs. no	1.283	1.203–1.369	
Adjuvant therapy			0.169
Yes vs. no	1.028	0.998–1.069	

PLOS, prolonged length of stay; HR, hazard ratio; CI, confidence interval.

postoperative complications. Due to the lack of relevant data of postoperative complications in the NCDB database, PLOS was therefore considered an alternative factor of complications after lung cancer surgery. To our knowledge, this study is the first to propose length of hospital stay as a quantitative indicator of postoperative complications. Our results showed less favorable long- and short-term survival in the PLOS group compared with the Non-PLOS group, which was consistent with the effect of postoperative complications of lung cancer in the previously reported studies (13,14).

As a quantitative indicator of postoperative complications, the poor prognosis of lung cancer caused by PLOS may be attributed to other multiple reasons: Infection is the most common postoperative complication of lung cancer, with the highest morbidity of 25% (15-17). The levels of inflammatory cytokines and C-reactive proteins will be increased by surgery in lung cancer patients. Colacchio *et al.* (18) showed that surgical stress response will increase the tumor load by inhibiting the activity of natural killer (NK) cells and downregulate the effector lymphocyte and their corresponding Th1 regulatory pathways via inhibiting endogenous mediators. This results in a promotive state of tumor growth and thereby the proliferation of residual tumor cells, which may reduce the long-term survival. Therefore, perioperative measures should be implemented systematically and normatively, including routine smoking cessation before operation, aerosol inhalation for airway preparation, expectoration training, administration of antibiotics before surgery, and getting out of bed early for expectoration after surgery (19).

Another dangerous postoperative complication of lung cancer is venous thromboembolism (VTE), including deep venous thromboembolism (DVT) and pulmonary embolism (PE) with a reported incidence rate of 15.1–16.4% (20,21). Studies have shown that the incidence of VTE within 7 days after lung cancer surgery is about 7.4% and the incidence of VTE within 30 days after surgery is about 23.1% (22,23). The incidence of VTE will be higher in advanced non-small cell lung cancer (NSCLC) and remains a higher tendency within half a year after the diagnosis of lung cancer (24). Among VTE, PE has a high mortality rate. Li *et al.* (25) revealed that hospital LOS was significantly prolonged

in patients with PE compared with patients without PE. Based on risk evaluation of VET, active preventive measures such as moving limbs early, wearing elastic socks, and early administration of low molecular weight heparin (LMWH) should be performed after lung cancer surgery.

In addition, previous study asserted that the negative psychological state of patients should also be included in the postoperative complications of lung cancer, such as cancer-related depression and anxiety, which can reduce the treatment compliance and prolong the hospital stay (26). Therefore, we also need to pay attention to the psychological management of lung cancer patients and carry out psychological intervention when necessary to minimize the psychological burden after surgery.

Limitations

This study may have some limitations. Firstly, tumor-specific survival indicators such as progression-free survival (PFS) and disease-free survival (DFS) are not available in the NCDB database, so we could only choose OS as a long-term prognosis indicator in our study. In addition, although we tried to exclude the influence of factors on LOS through PSM, there may have been other factors that contributed to prolonged hospitalization that were not included. However, based on the results of the study, lung cancer patients with prolonged postoperative hospital stay do have poor postoperative long- and short-term outcomes. More data and mechanisms are needed to confirm our results in the future.

Conclusions

In summary, our study showed that LOS in NCDB can predict survival after lung cancer surgery, and we found that PLOS was an independent prognostic factor for poor survival after lung cancer surgery. Appropriate measures to prevent complications and thus reduce the PLOS in lung cancer patients are likely to be beneficial for survival. The results of our study are exactly consistent with the concept of ERAS. Our study undoubtedly provides an important hint for perioperative management of lung cancer patients.

Acknowledgments

Funding: This work was supported by Science and Technology Commission of Shanghai Municipality (No. 21Y31900104 to J Zhang); Industry-University-

Research Projects of Shanghai University Teachers (No. RC.202111.001 to J Zhang); Scientific Research Project of Traditional Chinese Medicine of Shanghai Municipal Health Commission (No. 2020LZ004 to J Zhang); Collaborative Innovation Center for Clinical and Translational Science by Chinese Ministry of Education & Shanghai (No. CCTS-2022209 to J Zhang); Technology Transfer Promotion Program of Shanghai Jiao Tong University (No. ZT202113 to J Zhang).

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-407/rc>

Peer Review File: Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-407/prf>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-407/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. *CA Cancer J Clin* 2022;72:7-33.
2. Ettinger DS, Wood DE, Aisner DL, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. *J Natl Compr Canc Netw* 2021;19:254-66.

3. Petersen RH, Huang L, Kehlet H. Guidelines for enhanced recovery after lung surgery: need for re-analysis. *Eur J Cardiothorac Surg* 2021;59:291-2.
 4. Li R, Wang K, Qu C, et al. The effect of the enhanced recovery after surgery program on lung cancer surgery: a systematic review and meta-analysis. *J Thorac Dis* 2021;13:3566-86.
 5. McDevitt J, Kelly M, Comber H, et al. A population-based study of hospital length of stay and emergency readmission following surgery for non-small-cell lung cancer. *Eur J Cardiothorac Surg* 2013;44:e253-9.
 6. Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for Outcomes Research: A Review. *JAMA Oncol* 2017;3:1722-8.
 7. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2016;11:39-51.
 8. Cheng M, Zhang S, Ning C, et al. Omega-3 Fatty Acids Supplementation Improve Nutritional Status and Inflammatory Response in Patients With Lung Cancer: A Randomized Clinical Trial. *Front Nutr* 2021;8:686752.
 9. Bagan P, Berna P, De Dominicis F, et al. Nutritional status and postoperative outcome after pneumonectomy for lung cancer. *Ann Thorac Surg* 2013;95:392-6.
 10. Linares-Moya M, Rodriguez-Torres J, Heredia-Ciuro A, et al. Psychological distress prior to surgery is related to symptom burden and health status in lung cancer survivors. *Support Care Cancer* 2022;30:1579-86.
 11. Canet J, Gallart L, Gomar C, et al. Prediction of postoperative pulmonary complications in a population-based surgical cohort. *Anesthesiology* 2010;113:1338-50.
 12. Mazo V, Sabate S, Canet J, et al. Prospective external validation of a predictive score for postoperative pulmonary complications. *Anesthesiology* 2014;121:219-31.
 13. Rueth NM, Parsons HM, Habermann EB, et al. The long-term impact of surgical complications after resection of stage I nonsmall cell lung cancer: a population-based survival analysis. *Ann Surg* 2011;254:368-74.
 14. Nojiri T, Hamasaki T, Inoue M, et al. Long-Term Impact of Postoperative Complications on Cancer Recurrence Following Lung Cancer Surgery. *Ann Surg Oncol* 2017;24:1135-42.
 15. Radu DM, Jauregui F, Seguin A, et al. Postoperative pneumonia after major pulmonary resections: an unsolved problem in thoracic surgery. *Ann Thorac Surg* 2007;84:1669-73.
 16. Yao L, Luo J, Liu L, et al. Risk factors for postoperative pneumonia and prognosis in lung cancer patients after surgery: A retrospective study. *Medicine (Baltimore)* 2021;100:e25295.
 17. Lee JY, Jin SM, Lee CH, et al. Risk factors of postoperative pneumonia after lung cancer surgery. *J Korean Med Sci* 2011;26:979-84.
 18. Colacchio TA, Yeager MP, Hildebrandt LW. Perioperative immunomodulation in cancer surgery. *Am J Surg* 1994;167:174-9.
 19. Heiden BT, Eaton DB Jr, Chang SH, et al. Assessment of Duration of Smoking Cessation Prior to Surgical Treatment of Non-small Cell Lung Cancer. *Ann Surg* 2023;277:e933-40.
 20. Walker AJ, Baldwin DR, Card TR, et al. Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data. *Br J Cancer* 2017;116:e1.
 21. Akhtar-Danesh GG, Akhtar-Danesh N, Shargall Y. Venous Thromboembolism in Surgical Lung Cancer Patients: A Provincial Population-Based Study. *Ann Thorac Surg* 2022;114:890-7.
 22. Mason DP, Quader MA, Blackstone EH, et al. Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome. *J Thorac Cardiovasc Surg* 2006;131:711-8.
 23. Merkow RP, Bilimoria KY, McCarter MD, et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. *Ann Surg* 2011;254:131-7.
 24. Chew HK, Davies AM, Wun T, et al. The incidence of venous thromboembolism among patients with primary lung cancer. *J Thromb Haemost* 2008;6:601-8.
 25. Li YP, Shen L, Huang W, et al. Prevalence and Risk Factors of Acute Pulmonary Embolism in Patients with Lung Cancer Surgery. *Semin Thromb Hemost* 2018;44:334-40.
 26. Fitch MI, Steele R. Supportive care needs of individuals with lung cancer. *Can Oncol Nurs J* 2010;20:15-22.
- (English Language Editor: J. Jones)

Cite this article as: Kong W, Wang H, Chen Y, Xie J, Huang B, Fang L, Chen W, Shao W, Zhang J. Association between length of stay and postoperative survival in patients with lung cancer: a propensity score matching analysis based on National Cancer Database. *J Thorac Dis* 2023;15(4):1785-1793. doi: 10.21037/jtd-23-407